Emrusolmin

Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn) . Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology[1][2].

Product Specifications

CAS Number

[882697-00-9]

Product Name Alternative

Anle138b

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Amyloid-β

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/emrusolmin.html

Purity

99.93

Solubility

DMSO : 87.5 mg/mL (ultrasonic)

Smiles

BrC1=CC(C2=CC(C3=CC=C(OCO4)C4=C3)=NN2)=CC=C1

Molecular Formula

C16H11BrN2O2

Molecular Weight

343.17

Precautions

H315, H319, H335

References & Citations

[1]Wagner J, et al. Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathol. 2013 Jun;125 (6) :795-813.|[2]Martinez Hernandez A, et al. The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Mol Med. 2018;10 (1) :32-47.|[3]Heras-Garvin A, et al. Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Mov Disord. 2019;34 (2) :255-263.